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1. Introduction 
Addison’s disease, named after the English physician who provided its full description in 
1855, is the result of the destruction or impaired function of adrenocortical cells. Of the 11 
cases described by Addison, 10 were likely subsequent to an infiltrative disease (the most 
common being the secondary localization of Mycobacterium tuberculosis to the adrenal gland) 
and 1 was clinically idiopathic (likely of an autoimmune origin, on the basis of the current 
knowledge of disease mechanisms). In recent years the ethiologic spectrum of the disease 
has considerably expanded to include genetic causes not present in the 11 cases described by 
Thomas Addison. Accordingly, the definition of primary adrenal insufficiency (PAI) 
appears today more correct. Nevertheless, Autoimmune Addison’s Disease (AAD) and post-
tuberculosis Addison’s disease are still adequate definitions according to the clinical 
characteristics of the cases described in 1855.  
Prevalence of PAI is estimated at 120-160 cases per million in western countries, 
corresponding to 1 case every 7,000-7,500 individuals (Laureti et al, 1999; Løvås et al, 2002). 
The clinical manifestations of the disease result from the glucorticoid, mineralcorticoid and 
androgen deficiency (Oelkers, 1996). In western countries and Japan, an autoimmune 
process is responsible for the destruction of the adrenocortical cells and for the clinical 
manifestations of PAI in around 70-90% of cases (Betterle et al, 2002; Nomura et al, 1994).  
AAD occurs frequently in concomitance with other organ-specific and non-organ-specific 
autoimmune diseases in the so-called autoimmune polyendocrine syndromes (APS). Since 
at least two-thirds of patients with AAD have one or more other manifestations of an 
ongoing autoimmune process against other endocrine glands or different tissues, AAD can 
be considered a paradigmatic disease for the study of endocrine autoimmunity. On the basis 
of the type of diseases present in the same patient, different APSs are recognized. APS 1 is 
caused by mutations of the AIRE (AutoImmune REgulator) gene, which is located on 
chromosome 21 (The Finnish-German APECED Consortium, 1997). This syndrome is 
characterized by the concomitant presence of at least two of three diseases: chronic 
mucocutaneous candidiasis, hypoparathyroidism and AAD. In first-degree relatives of 
APS1 patients a single disease manifestation is sufficient to formulate the diagnosis. No 
general agreement exists for the classification of the remaining APSs. Some authors 
discriminate APS 2, APS 3 and APS 4 according to the different combination of  
autoimmune diseases present in the same patients. With this classification, APS 2 would 
identify the association of clinical or pre-clinical AAD with thyroid autoimmune diseases 
www.intechopen.com
  
Contemporary Aspects of Endocrinology 
 
356 
and/or type 1 diabetes mellitus (T1DM). APS 3 would be the association of thyroid 
autoimmune diseases with other endocrine and non-endocrine autoimmune manifestations 
(with the exception of AAD) and APS 4 would include all other possible combinations. No 
sound pathophysiological and/or genetic background, however, supports this classification, 
as the different endocrine autoimmune diseases tend to share a common genetic 
background and the same subject that might be initially be classified as APS 3 or APS 4 
would be reclassified as APS2 if clinical or subclinical signs of adrenal or thyroid 
autoimmunity occur at a later stage. Throughout this chapter we will then refer to APS 2 to 
include all combinations of AAD with other immuno-mediated diseases, different from 
hypoparathyroidism or chronic mucocutaneous candidiasis.  
Most frequently AAD is associated with Hashimoto’s thyroiditis or Graves’s disease, one or 
the other being present in over 50% of patients with autoimmune adrenal insufficiency 
(Betterle et al, 2002; Nerup, 1974; Kong et al, 1994; Irvine et al, 1967, 1979; McHardy-Young et 
al, 1974; De Rosa et al, 1987; Papadopoulos et al, 1990; Kasperlik-Zaluska et al, 1991; Zelissen 
et al, 1995; Söderbergh et al, 1996; Neufeld et al, 1981). Atrophic gastritis is present in 20-25% 
of AAD patients, while type 1 diabetes mellitus (T1DM) has been reported in 1-20% of 
addisonian patients (Betterle et al, 2002; Nerup, 1974; Kong et al, 1994; Irvine et al, 1967, 1979; 
McHardy-Young et al, 1974; De Rosa et al, 1987; Papadopoulos et al, 1990; Kasperlik-Zaluska 
et al, 1991; Zelissen et al, 1995; Söderbergh et al, 1996; Neufeld et al, 1981). 
Hypergonadotropic hypogonadism is present in 4.5-19% of AAD women. Other 
autoimmune diseases found associated with AAD at lower frequency include: vitiligo, 
alopecia, celiac disease, pernicious anemia, multiple sclerosis, inflammatory bowel disease, 
Sjögren’s syndrome, chronic hepatitis and lymphocytic hypophysitis (Betterle et al, 2002; 
Nerup, 1974; Kong et al, 1994; Irvine et al, 1967, 1979; McHardy-Young et al, 1974; De Rosa et 
al, 1987; Papadopoulos et al, 1990; Kasperlik-Zaluska et al, 1991; Zelissen et al, 1995; 
Söderbergh et al, 1996; Neufeld et al, 1981).   
2. Adrenal autoimmunity 
The human adrenal autoimmune process is made evident by the apperance of circulating 
autoantibodies directed against the adrenal cortex or its components, which can be detected 
in the serum of affected individuals.  
The first demonstration of adrenal cortex autoantibodies (ACA), detected by a complement- 
fixation test in the sera from patients with AAD, was provided in 1957 (Anderson et al, 
1957). The use of the indirect immunofluorescence (IIF) approach, introduced by Blizzard 
and Kyle, 1963, has subsequently enabled the development of more sensitive assays for the 
detection of ACA (Blizzard et al, 1963, 1967; Goudie et al, 1966; Andrada et al, 1968; Wuepper 
et al, 1969; Nerup, 1974; Irvine & Barnes, 1974; Sotsiou et al, 1980; Elder et al, 1981; 
Papadopoulos et al, 1990). ACA  have been detected in 40-75% patients with clinically 
idiopathic Addison’s disease (Blizzard et al, 1963, 1967; Goudie et al, 1966; Andrada et al, 
1968; Wuepper et al, 1969; Nerup, 1974; Irvine & Barnes, 1974; Sotsiou et al, 1980; Elder et al, 
1981; Stechmesser et al, 1985; Kosowicz et al, 1986; Papadopoulos et al, 1990). Differences in 
the substrate used for detection of autoantibodies (human vs. animal adrenals), in disease 
duration and in selection of patients are responsible for the high variability in ACA 
frequency in patients with PAI. 
In spite of the very well known technical limitations, because of the relative simplicity of the 
assay and the high diagnostic sensitivity, ACA-IIF have represented the gold standard for 
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adrenal autoantibody determination until the middle of the ‘90s. ACA react with cytoplasm 
autoantigen(s) of cells located in all three layers of the adrenal cortex. More recent studies 
have detected ACA in approximately 80% of patients with AAD, representing over 90% of 
patients with recent-onset disease and 79% with long-standing disease (>2 years of disease 
duration) (Betterle et al, 1999). ACA are more frequent in patients with APS1 or APS2 than in 
patients with isolated Addison’s disease (Betterle et al, 1999).   
Attempts to identify the molecular targets of ACA started during the 1980’s, which  led to 
the initial identification of a 55-kDa autoantigen present in human adrenal microsomes 
(Furmaniak et al, 1988). Subsequent studies of the beginning of the 1990’s have identified  
steroid-21-hydroxylase (21OH) as the main autoantigen target of ACA (Winqvist et al, 1992; 
Baumann-Antczak et al, 1992; Bednarek et al, 1992). Around  the same time, steroid-17-
hydroxylase (17OH) (Krohn et al, 1992) and P450 side chain cleavage (P450scc) enzyme 
(Winqvist et al, 1993) were identified as additional autoantigens.  
The discovery of the molecular targets of ACA led to development of radiobinding assays 
with radiolabelled human autoantigen. The use of either in vitro translated 35S-21OH 
(Falorni et al, 1995, 1997; Colls et al, 1995) or 125 I-21OH (Tanaka et al, 1997) has enabled the 
demonstration that 21OH autoantibodies (21OHAb) have a high diagnostic sensitivity and 
specificity for AAD, being detected in over 95% of cases with clinically idiopathic adrenal 
insufficiency. The major epitopes recognised by human 21OHAb are located in the central 
and COOH-terminal domains of the enzyme. In addition, naturally occurring mutations, 
associated with the development of congenital adrenal hyperplasia, inhibit the binding of 
human autoantibodies to recombinant 21OH (Chen et al, 1998, Nikoshkov et al, 1999). In vitro 
studies (Furmaniak et al, 1994) have shown that 21OHAb may inhibit the enzymatic activity 
of the autoantigen, but this finding has not been confirmed in vivo, during the natural 
history of the disease (Boscaro et al, 1996; Laureti et al, 2002).  
Similarly to other organ-specific autoantibodies, 21OHAb have no major pathogenic role in 
the development of adrenal insufficiency, as they can be detected in approximately 1/200 
healthy subjects who do not necessarily progress towards clinical adrenal insufficiency. 
During pregnancy, 21OHAb cross the placental barrier, but do not determine any sign of 
clinical or pre-clinical adrenal insufficiency in the newborn (Betterle et al, 2004). Hence, 
21OHAb are a highly senstive and specific immunological marker of the ongoing adrenal 
autoimmune process, but do not act as an effector of the destructive autoimmune process.  
Our group has recently shown that 21OHAb are predominantly IgG1, with a minor 
expression of IgG2 and IgG4, which demonstrates a Th1-oriented type of immune response 
(Brozzetti et al, 2010a). However, approximately 10% of AAD patients express IgG4-
21OHAb in the absence of IgG1 (Brozzetti et al, 2010a). This type of IgG subclass selection 
reveals a more Th2-oriented type of activation. At present, it is still unclear whether this 
distinct subgroup of patients with a more Th2-oriented type of immune response represents 
a different population of AAD subjects or is the expression of a different stage of the natural 
history of the disease. 
 Although 17OHAb and P450sccAb can be detected in a small fraction of patients with AAD, 
these markers are more frequently present in patients with APS 1 or in women with 
autoimmune oophoritis which causes autoimmune ovarian insufficiency (see paragraph on 
Ovarian Autoimmunity) (Betterle et al, 1999; Perniola et al, 2000; Falorni et al, 2002a).  
Diagnosis of PAI is based on clinical ground and hormonal determination, but the ethiologic 
diagnosis of AAD requires detection of circulating 21OHAb, by using a radiobinding assay. 
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Autoantibody titer is also important, because the presence of low titre adrenal 
autoantibodies does not enable the unequivocal diagnosis of AAD in all cases (Falorni et al, 
2004). ACA and 21OHAb have sporadically been found also in patients with unequivocal 
post-tuberculosis Addison’s disease (Nomura et al, 1994; do Carmo Silva et al, 2000). A flow-
chart for the etiological classification of PAI, that takes into consideration immunological, 
biochemical and imaging data, has been developed by the Italian Addison Network (Falorni 
et al, 2004). Published data indicate that the diagnostic accuracy of the 21OHAb assay is 
higher than that of the ACA-IIF (Falorni et al, 2004), and 21OHAb is currently the gold 
standard for detection of adrenal autoantibodies. In the case of a simultaneous presence of 
both ACA and 21OHAb, the probability of an accurate diagnosis of AAD is higher than 99% 
(Falorni et al, 2004). All patients with AAD should undergo additional autoantibody 
analyses, such as thyroid autoantibodies, GAD autoantibodies (GADA), steroid-cell 
autoantibodies (StCA), 17OHAb, P450sccAb or parietal cell autoantibodies, as 
approximately two thirds of AAD patients show clinical or pre-clinical signs of another 
autoimmune disease. Autoimmune AAD can be diagnosed also in the presence of medium-
high levels of either 21OHAb or ACA (Falorni et al, 2004). In the case of patients positive 
only for 21OHAb or ACA at low levels, as well as in autoantibody-negative subjects, adrenal 
imaging should be performed to exclude an infiltrative form of adrenal insufficiency (such 
as post-tuberculosis, sarcoidosis, mycosis or metastatic localization of non-adrenal tumours) 
(Falorni et al, 2004). In male patients negative for both adrenal autoantibody measurement 
and  adrenal imaging analysis, determination of plasmatic very long chain fatty acids 
(VLCFA) must be performed to exclude X-linked adrenoleukodystrophy (ALD).  
At present, no clear and standardised cut-off is available to discriminate between low and 
medium-high level autoantibody titers and worskhops for the standardization of adrenal 
autoantibody assays are strongly needed. In a first international serum exchange to compare 
the results of 21OHAb determination in four independent laboratories, a good positive-
negative concordance was observed, but major discrepancies emerged in quantitation of 
autoantibody titre (Falorni et al, 2011). A European program for the standardization of 
21OHAb assay is currently being organised, and is expected to be completed within 2012.  
Screening of subjects with endocrine autoimmune diseases for the presence of 21OHAb 
enables the identification of subjects with so-called preclinical AAD, which is characterised 
by the presence of adrenal autoantibodies in the absence of clinical signs of adrenal 
insufficiency and in the presence of normal basal cortisol concentrations. In patients with 
autoimmune diseases, 21OHAb can be detected in around 0.5-1.5% T1DM patients, 0.5-1.5% 
patients with autoimmune thyroid diseases, 0.5-1.0% patients with vitiligo and in 4-8% 
women with primary ovarian insufficiency (Betterle et al, 2002). 21OHAb-positive 
individuals exhibit a variable degree of adrenal dysfunction that can be classified in four 
different stages (Betterle et al, 1988).  
Stage 0 indicates the apperance of adrenal autoantibodies, as a sign of the ongoing adrenal 
autoimmune process. 21OHAb appears before ACA, and lasts longer than ACA, during the 
natural history of the disease.  
Often the first dysfunction observed as a consequence of the  progression of the 
autoimmune process is an initial increase of plasmatic renin activity (PRA), at a time when 
normal ACTH-cortisol axis response is still present (stage 1). In stage 2, an impaired response 
to the ACTH stimulation test is documented, while the final stage 3 represents the pre-
clinical stage characterized by increased basal ACTH levels, along with the dysfunctions 
observed in stage 1 and 2.  
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No preventative therapy is yet available to delay or block the progressive destruction of 
adrenocortical cells in pre-clinical AAD. An Italian study has shown that an 
immunosuppressive therapy with high-dose corticosteroids for the treatment of Graves’ 
ophthalmopathy had been able to revert a stage 2 pre-clinical AAD in a 21OHAb-positive 
individual (De Bellis et al, 1993). As a result of the treatment, disappearance of adrenal 
autoantibodies and normalization of both ACTH-cortisol and PRA-aldosterone axis function 
was observed and maintained for over 10 years at follow-up (De Bellis et al, 1993). However, 
the possibility to revert an advanced pre-clinical adrenal insufficiency by high-dose steroid 
immunosuppression has not yet been confirmed in other independent studies and it is not 
recommended for the sole purpose of preventing the progression towards clinical AAD.   
Among the factors associated with progression towards clinical adrenal insufficiency are 
adrenal autoantibody levels that tend to increase during the progression of the adrenal 
dysfunction (Betterle et al, 1997).  
Approximately 80% of patients with stage 0 and stage 1 do not progress to clinical AAD and 
may show a spontaneous remission of the pre-clinical dysfunction (Laureti et al, 1998). On 
the other hand, no such spontaneous remission seems to occur in patients with stage 2 and 
stage 3, in whom progression to clinical AAD is observed in over 95% of cases. A 
matematical formula that takes into consideration all known factors influencing risk of 
progression towards clinical AAD has been generated (Coco et al, 2006). 
In subjects positive for 21OHAb and/or ACA, an ACTH stimulation test discriminates 
between a potentially reversible and an irreversible stage of the pre-clinical dysfunction. It 
has been shown that the high-dose 250 g of synthetic ACTH used in the classical ACTH 
test (HDT) is supra-maximal and that as little as 1 g of synthetic ACTH can determine a 
maximal stimulation of the adrenocortical cells (Arvat et al, 2000). The low-dose test with 1 
g of ACTH (LDT) has a high diagnostic sensitivity and specificity for pre-clinical adrenal 
dysfunction and can substitute the classical high-dose test (Laureti et al, 2000, 2002). An 
ongoing European multicenter study is currently testing the diagnostic accuracy and the 
predictive value of a 0.5 g low-dose ACTH test.   
Among the factors increasing significantly the risk of progression towards clinical adrenal 
insufficiency, in subjects with subclinical AAD, the most important are: male gender, 
presence of other concomitant autoimmune diseases, impaired response to the LDT and a 
high 21OHAb titer (Coco et al, 2006). HLA-DR3-DQ2, DR4-DQ8 and CTLA-4 gene 
polymorphism are significantly associated with appearance of 21OHAb, but do not 
influence the natural history of the disease and do not predict future clinical adrenal 
insufficiency (Coco et al, 2006; Falorni et al, unpublished data). Homozygosity for MICA5.1 
was found to increase significantly the risk of progression towards clinical adrenal 
insufficiency (Barker et al, 2005), but larger, prospective studies are needed to confirm this 
finding. Because of the high predictive value of 21OHAb for future AAD, which is higher 
than 30% at 10 years of follow-up, screening of patients with ongoing endocrine 
autoimmune diseases with this marker is recommended to identify subjects with pre-clinical 
adrenal insufficiency. 
3. Genetics of autoimmune adrenal insufficiency 
Autoimmune Regulator (AIRE) is the causative gene for APS1 (The Finnish-German 
APECED Consortium, 1997). The AIRE gene product, Aire, acts as a strong activator of 
transcription (Pitkänen et al, 2000, 2001; Björses et al, 2000). Over 60 disease-associated 
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mutations of the AIRE gene have been so far identified. Many mutations are located in the 
homogeneously staining region (HSR) in the N-terminal end of the protein. Other 
mutations, such as C311Y, P326Q, L397fsX478 are located in the plant homeodomain zinc 
finger 1 and 2, while only a few mutations, such as G228W or R257X have been identified in 
the DNA binding motif (Bottomley et al, 2001). It has been reported that a kindred carrying 
the G228W variant presented with an autosomal dominant autoimmune phenotype 
manifesting predominantly with thyroidits and distinct from APS1 (Cetani et al, 2001). The 
generation of a G228W-knocking mouse model showed that this AIRE variant acts in a 
dominant-negative manner causing a unique autoimmune syndrome (Su et al, 2008).  
Disease-associated AIRE mutations are highly conserved within defined geographical areas. 
The R257X is the most frequently found mutation in Northern Italy and in Finland, while 
964del13 is the most common mutation in the UK. In Sardinia, R139X is the typical AIRE 
mutation found in APS 1 patients. 
Outside APS1, AAD shares many predisposing genetic factors with other endocrine 
autoimmune diseases that are components of APS2, such as thyroid autoimmune diseases and 
T1DM, the major genetic markers associated with the diseases beeing located in the HLA 
region on chromosome 6. The disease is strongly and positively associated with both HLA-
DRB1*0301-DQA1*0501-DQB1*0201 (DR3-DQ2) and DRB1*04-DQA1*0301-DQB1*0302 (DR4-
DQ8) (Falorni et al, 2008). The HLA-DRB1*01-DQA1*01-DQB1*0501 and DRB1*13-DQA1*0103-
DQB1*0603 haplotypes are negatively associated with genetic risk for AAD. Several studies 
have shown that the association of HLA class II haplotypes is still highly significant in patients 
with isolated AAD and does not depend on the coexistence of other autoimmune disorders in 
the same patient. DRB1-*0404 was more frequent among DRB1*04-positive AAD patients from 
US (Yu et al, 1999) and Norway (Myhre et al, 2002) as compared to both DRB1*04-positive 
healthy control subjects and DRB1*04-positive T1DM patients. The DRB1*0401 subtype was 
strongly and positively associated with T1DM, but not with AAD (Yu et al, 1999; Myhre et al, 
2002). However, an Italian study from our group (Gambelunghe et al, 2005) did not confirm 
this hypothesis. In that study (Gambelunghe et al, 2005), it was observed that no statistically 
different distribution of DRB1*0401 and DRB1*0404 was detectable among T1DM patients and 
AAD patients. On the other hand, it was observed that the DRB1*0403 subtype, which was 
already known to confer strong protection for T1DM, was absent among 56 DRB1*04-positive 
AAD patients, but present in 27 % DRB1*04-positive healthy control subjects, thus conferring 
protection also for the development of AAD.     
Other HLA genes contribute to the risk for AAD, among which the MHC class I chain-
related A (MICA) gene polymorphism. The MICA gene encodes for a ligand for an 
activating receptor (NKG2D) present on  T cells, CD8+CD28-  T cells, natural killer cells 
and CD4+CD28-  cells and is located within the HLA class III region. There are 
speculations that MICA gene polymorphism might influence affinity for the NKG2D 
receptor. AAD is strongly associated with the transmembrane MICA 5.1 allele, with odds 
ratio similar to those observed for HLA class II haplotypes (Gambelunghe et al, 1999; Park et 
al, 2002). MICA6 appears to be negatively associated with disease risk for AAD 
(Gambelunghe et al, 1999).  
Though the association of MICA with AAD appears to be independent from that with HLA 
class II haplotypes, the strong linkage disequilibrium existing within the DRB1*03-
DQA1*0501-DQB1*0201-MICA5.1-HLA-B extended haplotype has so far limited the 
possibility to discriminate the relative contribution of each gene marker and further studies 
on large populations are needed to provide an answer to this specific question. 
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Similarly to T1DM and other autoimmune diseases, the genetic background for AAD 
includes also other genes believed to modulate the function of the immune system. The 
CTLA-4 gene polymorphism and the PTPN22 gene polymorphism have been found to 
modulate genetic risk for AAD (Falorni et al, 2008; Skinningsrud et al, 2008a). A recent 
metanalysis of European studies has confirmed that the CTLA-4 Ala 17 polymorphism is 
strongly associated with genetic risk for AAD, independentenly from the well known 
association with the polymorphism of HLA class II genes (Brozzetti et al, 2010b). 
Two independent European studies have shown the association of the class II transactivator 
(CIITA) (also denominated MHC2TA) gene with AAD (Ghaderi et al, 2006; Skinningsrud et 
al, 2008b). Modulation of the expression of HLA class II determinants in antigen-presenting 
cells may represent a critical factor in the activation and maintenance of the organ-specific 
autoimmune process and genetic factors that may influence such expression may have an 
important role on the pathogenesis of autoimmune diseases. The regulatory factor X 
complex (RFX) and CIITA are essential and specific for activation of class II promoters 
(Durand et al, 1997; Masternak et al, 1998; Reith  & Mach, 2001; Nekrep et al, 2002). More 
specifically, the class II expression on antigen presenting cells is under the control of CIITA, 
that exhibits cell-specific, cytokine-inducible and differentiation-specific expression and is 
expressed in the same cells that express class II molecules, such as B cells, monocytes, 
dendritic cells and activated T cells. The genetic association of CIITA with AAD appears to 
be independent from that with HLA gene markers.  
Other reported AAD genetic associations include the vitamin D receptor and the CYP27B1 
(25-hydroxyvitamin D3-1-hydroxylase) gene and the NACHT leucine-rich-repeat protein 1 
(NALP1) gene (Magitta et al, 2009). 
4. Pathophysiology of AAD 
No model of spontaneous autoimmune primary adrenal insufficiency is yet available. 
Experimental autoimmune adrenalitis has been induced in mice, guinea pigs, rats and 
monkeys by injection of adrenal homogenates mixed with adjuvants (Betterle et al, 2002), with 
a resulting delayed type of hypersensitivity to adrenal antigens, rather than the induction of an 
adrenal autoimmune process. No conclusive data are yet available on the possibility of 
inducing an autoimmune reaction by injecting the major adrenal autoantigen 21-hydroxylase. 
The current unavailability of a reliable animal model of spontaneous adrenal autoimmunity 
similar to the human disease, has so far limited the studies on the pathophysiology of AAD. 
Major efforts are being profused to develop an animal model of AAD that may prove useful 
for the understanding of the molecular mechanisms responsible for the human disease. 
The effector cells of the autoimmune-mediated destruction of adrenocortical cells are 
thought to be T lymphocytes (Hayashi et al, 1989; Freeman & Weetman, 1992). Nerup et al., 
1969, 1970, showed that patients with autoimmune adrenal insufficiency have T cells 
reactive against fetal adrenal extracts or adrenal mitochondrial fraction. Subsequently, it 
was shown that patients with recent-onset AAD have an increased expression of circulating 
Ia-positive T cells when compared to healthy control subjects (Rabinowe et al, 1984). 
Freeman & Weetman, 1992 were able to demonstrate T cell proliferation in response to 
stimulation with adrenal proteins fractionated according to molecular weight. Patients with 
autoimmune polyendocrine syndrome type II, but not individuals with isolated Addison’s 
disease,  seem to have CD4+CD25+regulatory T cells with defective suppressive capacity 
(Kriegel et al, 2004; Coles et al, 2005).  
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Although several studies support the hypothesis of a major role of cellular immunity in the 
autoimmune destruction of the adrenocortical cells in Addison’s disease, little is known of 
the individual antigens recognised by autoreactive T cells. Husebye et al. immunized 
BALB/c and SJL mice with recombinant 21OH and showed a selective significant 
proliferative response of T cells from lymph nodes against the peptide 342-361 of 21OH that 
corresponds to the substrate binding site of the enzyme (Husebye et al, 2006).  
Among Th cell subtypes, two main subtypes, denominated Th1 and Th2, are recognized. 
AAD is thougth to result from an unbalance of Th1/Th2 responses with a predominance of 
Th1 activity. Chemokines produced at the site of inflammation participate by recruiting T 
cells and by sustaining the immune reaction (Rotondi et al, 2007). Th1 cells mainly express 
CXCR3 and are recruited at the site of inflammation by CXCL9, CXCL10  and CXCL11. Th2 
cells express different chemokine receptors, such as CCR4 and CCR8, thus being recruited in 
target tissues by CCL17, CCL22 and CCL1. The existence of an important IFN--mediated 
pathogenetic loop has been proposed for endocrine autoimmunity, as release of CXCR3-
binding chemokines is stimulated by IFN- and, in turn, these chemokines recruit Th-1 cells 
that produce IFN-(Rotondi et al, 2007).  
In one report concerning the role of serum CXCL10 in AAD, serum levels of CXCL10 were 
significantly increased in patients with either clinically evident or subclinical adrenal 
insufficiency, as compared to healthy control subjects (Rotondi et al, 2005). The absence of a 
gender-related effect in AAD, either isolated or occurring within APS-2, suggested that 
autoimmune adrenalitis by itself was responsible for the high circulating levels of CXCL10. 
In the same study (Rotondi et al, 2005), it was also shown that release of CXCL10 by primary 
cell cultures of human zona fasciculata cells (hZFC) was undetectable basally, but 
significantly induced by stimulation with IFN- or IFN- plus TNF-, while stimulation of 
hZFC with TNF- alone was not able to induce chemokine secretion. Interestingly, 
increasing concentrations of hydrocortisone progressively and significantly inhibited IFN--
induced and IFN-- plus TNF--induced CXCL10 secretion (Rotondi et al, 2005). 
The inhibitory effect of glucocorticoids on chemokine production is in line with their 
antiinflammatory and immunosuppressive actions. Glucocorticoids are able to suppress the 
production of several cytokines and chemokines by inhibiting the nuclear factor-B and by 
activating protein-1 transcription factor families (Karin, 1998).  
More recently, increased serum levels of Th1-related chemokines CXCL10 and macrophage 
inflammatory proteins 1alpha (CCL3/MIP-1alpha) and of the Th2- related chemokine 
macrophage inflammatory proteins 1 beta (CCL4/MIP-1beta) were observed in patients 
with AAD, which confirms the role of these chemokines in the autoimmune pathology of 
adrenal gland through the recruitment in loco of Th1 and Th2 cells (Bellastella et al, 2011).  
Based on the above described body of evidence, we can hypothesize that Th1 cells play a major 
pathogenetic role, while autoantibody production is a side effect with no pathogenic relevance. 
The decrease in Treg activity is probably one of the main mechanisms at the basis of the 
unbalanced activity of Th1 cells. The active role of the adrenocortical cells in modulating the 
autoimmune inflammation, by producing Th1-attracting chemokines and cortisol, should not 
be underestimated. Based on knowledge derived from studies on ovarian autoimmunity 
(Samy et al, 2005), it is likely that the continuous drainage of autoantigens to regional lymph 
nodes be essential to maintain an adequate activity of antiinflammatory Treg cells and that the 
reduced activity of Tregs and the unbalance Th1/Th2 ratio observed in human endocrine 
autoimmunity occur at the site of regional lymph nodes. 
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5. Ovarian autoimmunity 
Although it has been proposed that up to 30% of cases of primary ovarian insufficiency 
(POI) would have an autoimmune origin (Meskhi et al, 2006; Calongos et al, 2009), a more 
accurate estimate indicates that a documented ovarian autoimmune reaction is  present in 
not more than 4-5% of women with ovarian insufficiency (Hoek et al, 1997; Bakalov et al, 
2005).  
Similarly to the study of adrenal autoimmunity, the unavailability of an animal model of 
spontaneous autoimmune oophoritis has limited the possibility to define the molecular 
mechanisms of immune-mediated ovarian insufficiency. The animal model of neonatal 
thymectomy has proven instrumental to unravel the critical role of CD4+CD25+ regulatory T 
(Treg) cells (Samy et al, 2006) in suppressing autoimmune processes in regional lymph 
nodes, under a continuous stimulation by autologous antigens (Samy et al, 2005). The 
ovarian autoantigen identified in the animal model of neonatal thymectomy is the ooplasm-
specific MATER (Maternal Antigen That Embryo Requires)  protein.  
Immunization of mice with a peptide of inhibin alpha chain induced an initial increase in 
fertility, mediated by high serum levels of inhibin alpha neutralizing antibodies, that 
prevented inhibin-mediated downregulation of activin-induced FSH release (Altuntas et al, 
2006). In a second, delayed phase, the activation of CD4+ T-cells resulted in a lymphocytic 
infiltration of the ovary that occurred in parallel with a progressive decrease in fertility and 
ovarian function (Altuntas et al, 2006).  
However, it is still unclear to what extent these animal models are similar to human 
autoimmune POI.  
Several lines of evidence support the autoimmune origin of a fraction of POI cases. Some 
autoimmune diseases are more frequent in women with POI than in the general population, 
and, conversely, POI occurs more frequently in women affected by some autoimmune 
diseases than in other women. Approximately 15% of women with POI present with 
autoimmune thyroiditis (Hoek et al, 1997) and the frequency of POI is higher in women with 
T1DM than in the general population (Hoek et al, 1997). However, it must be noted that 
biochemical and/or ultrasound signs of thyroiditis can be detected in 10-15% women in the 
general population and that the concomitant association of POI and thyroiditis or POI and 
T1DM in the same woman does not justify per se a diagnosis of “autoimmune POI”. Surely 
more relevant is the association between POI and AAD (Betterle et al, 2002; Hoek et al, 1997; 
Falorni et al, 2002b). Approximately 4-8% of women with POI are positive for circulating 
adrenal autoantibodies, a frequency significantly higher than that expected in the general 
population (<0.5%) (Betterle et al, 2002; Falorni et al, 2002b). On the other hand, 10-20% of 
women with AAD develop POI before the age of 40 years (Betterle et al, 2002).  
The existence of ovarian autoantibodies was first shown in the 1960’s in studies that used 
indirect immunofluorescence on cryostatic sections of adrenal, ovary, testis and placenta 
(Blizzard et al, 1967; Irvine & Barnes, 1974). Subsequent studies have repeatedly confirmed 
the existence of ovarian autoantibodies in women with POI (Sotsiou et al, 1980; Elder et al, 
1981; Ahonen et al, 1987; Betterle et al, 1993). Ovarian autoantibodies detected by indirect 
immunofluorescence cross-react with autoantigens expressed in other tissues, mainly the 
adrenal cortex, the testis and the placenta, which indicates that the autoantigen(s) 
recognized by these autoantibodies are not restricted to the ovary, but expressed also in 
other organs. Hence, a more correct definition of these autoantibodies is that of Steroid-Cell 
Autoantibodies (StCA). Interestingly, although all the tissue components are present in the 
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ovarian cryostatic sections used for the autoantibody assay, the immunofluorescence pattern 
of StCA is restricted to the theca cells of the growing follicle with no staining of primary 
follicles or granulosa cells in secondary and tertiary follicles. The same autoantibodies stain 
specifically Leydig cells of the testis.   
Although indirect immunofluorescence is still the most widely used method to detect 
ovarian autoantibodies in clinical practice, the accuracy of this method has been questioned, 
mostly because of a low diagnostic specificity (Novosad et al, 2003). Some of the 
autoantigens recognised by StCA have been identified as the steroidogenic enzymes 17-
hydroxylase (17OH) and side-chain cleavage (P450scc) (Chen et al, 1996; Perniola et al, 2000; 
Falorni et al, 2002b). The development of immunoradiometric assays, using in vitro 
translated recombinant human 35S-radiolabelled autoantigens, have enabled the estimate of 
the diagnostic sensitivity and specificity of 17OHAb and P450sccAb for autoimmune POI 
(Chen et al, 1996; Perniola et al, 2000; Falorni et al, 2002b).  
17OHAb and P450sccAb are each present in 50 to 80% of women positive for StCA (Chen et 
al, 1996; Perniola et al, 2000; Falorni et al, 2002b). Over 90% of StCA-positive women are 
positive for 17OHAb and/or P450sccAb, which is demonstrating that 17OH and P450scc are 
major targets of StCA, but other autoantigens may also be recognized by a subset of StCA.  
StCA, 17OHAb and/or P450sccAb can be detected almost exclusively in women with POI 
who are also positive for adrenal autoantibodies, most specifically 21OHAb. The association 
of steroid-cell autoimmunity with adrenal autoimmunity is so strong that 21OHAb appear 
to be the marker at highest diagnostic sensitivity for autoimmune POI (Perniola et al, 2000; 
Falorni et al, 2002b, Bakalov et al, 2005). Since only less than 0.5% of women with POI can be 
found positive for StCA in the absence of 21OHAb, 17OHAb or P450sccAb, we can conclude 
that unequivocal biochemical signs of ovarian autoimmunity against steroidogenic enzymes 
are present almost exclusively in women with clinical or pre-clinical AAD.  
Several studies have demonstrated that an autoimmune oophoritis can be found at ovarian 
biopsy only in women positive for ovarian and/or adrenal autoantibodies (Irvine, 1980; 
Gloor & Hurlimann, 1984; Sedmak et al, 1987; Bannatyne et al, 1990; Hoek et al, 1997; 
Bakalov et al, 2005), thus confirming that steroidogenic cell autoantibodies identify women 
with an ongoing ovarian autoimmune process. On the other hand, in the absence of ovarian 
and adrenal autoantibodies, no histological sign of autoimmune infiltration can typically be 
detected at ovarian biopsy, even in women who present with other autoimmune diseases, 
such as thyroiditis, T1DM, inflammatory bowel disease or systemic lupus erithematosus. 
Accordingly, a classification of autoimmune POI cannot be based only on the presence of 
other autoimmune manifestations, in the absence of specific autoantibodies in the serum.  
Autoimmune oophoritis is characterized by a selective mononuclear cell infiltration into the 
theca layer of large, antral follicles, with earlier stage follicles consistently free of 
lymphocytic infiltration (Hoek et al, 1997; Bakalov et al, 2005). This finding is in line with the 
selective staining of theca cells at the indirect immunofluorescence assay and confirms that 
the steroidogenic cell ovarian autoimmune process is mainly directed against theca cells.   
The absence of steroidogenic cell autoantibodies does not exclude the possibility that other 
autoantibodies may be present and other autoimmune mechanisms may be active. Many 
other potential autoantigens, such as LH receptor (Moncayo et al, 1989), FSH receptor (Ryan 
& Jones, 2004), zona pellucida (Kelkar et al, 2005), 82-86 kDa Ags and 52-63 kDa Ags 
(Wheatcroft et al, 1997) have been proposed as markers of ovarian autoimmunity, but the 
association of these autoantibodies with POI has not been confirmed (Anasti et al, 1995; 
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Tonacchera et al, 2004). Only detection of autoantibodies against steroidogenic enzymes can, 
accordingly, ensure, at present, an accurate identification of women with autoimmune 
oophoritis. Using these autoantibody markers, autoimmunity accounts for approximately 4-
5% of all POI cases.   
Along with the decline of serum concentrations of estradiol, POI is typically characterized 
with a reduction in synthesis and secretion of inhibins (Petraglia et al, 1998) and anti-
müllerian hormone (AMH) (Méduri et al, 2007), as a result of the progressive decline in 
ovarian function. In an initial study of three women with autoimmune POI (Welt et al, 2005) 
this general paradigma was however questioned, as increased serum concentrations of 
inhibin B were detected. This initial finding was confirmed in a subsequent larger study 
(Tsigkou et al, 2008) that demonstrated increased levels of serum inhibin B and total inhibin 
in a group of 22 women with autoimmune POI, as compared to 71 women with idiopathic, 
non-autoimmune POI and 90 healthy fertile women. The results of these studies (Welt et al, 
2005; Tsigkou et al, 2008) led to the formulation of a novel hypothesis of the 
pathophysiology of  autoimmune POI. Differently from other forms of ovarian insufficiency, 
in which a general reduction of ovarian function can be observed, autoimmune POI is 
characterized by the selective autoimmune destruction of theca cells with preservation of 
granulosa cells that produce low amounts of estradiol because of lack of substrates. The 
subsequent increase in FSH levels stimulates viable granulosa cells that, in return, produce 
increased amounts of inhibins.  
AMH levels have been found to be normal in women with hypogonadotrophic amenorrhea 
while they are very low or undetectable in women with physiological menopause or 
hypergonadotrophic amenorrhea (POI) (Méduri et al, 2007; La Marca et al, 2006; Knauff et al, 
2009). AMH is exclusively produced by primary and pre-antral/small antral follicles, and 
the immunohistochemical findings of the absence of an inflammatory reaction around 
primary follicles (Hoek et al, 1997; Bakalov et al, 2005) provided a sound rationale to estimate 
AMH production in women with autoimmune POI. We recently documented normal serum 
AMH concentrations in two-thirds of women with recently diagnosed autoimmune POI (La 
Marca et al, 2009), which provides the first demonstration of the existence of a subgroup of 
women with POI with a preserved ovarian follicle pool for several years. Since AMH is the 
best biochemical marker of residual follicle pool, the results of our study (La Marca et al, 
2009) are highly relevant for the future planning of clinical trials of immunotherapy aimed 
at preserving the residual functional tissue and/or delay the progression of the destructive 
ovarian autoimmune process in women with autoimmune POI. 
6. Conclusions 
Autoimmune Addison’s disease is made evident by the apperance of circulating 21OHAb, 
the gold immune marker for the identification of subjects with an ongoing adrenal 
autoimmune process. The appearance of 21OHAb marks pre-clinical autoimmune 
Addison’s disease, in asymptomatic subjects. In these individuals, the response to the 
ACTH-stimulation test enables the discrimination of an early, potentially reversible phase, 
from an irreversible phase of the disease. 
POI affects around 1% of women below the age of 40 years and the detection of steroid cell 
autoantibodies enables the identification of autoimmune cases. At present, only the 
detection of 21OHAb and 17OHAb or P450sccAb may accurately identify autoimmune cases 
of POI.    
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Although autoantibodies are widely used in clinical practice, they have no pathogenic role 
for either AAD or POI and these diseases are thought to be the consequence of a T-cell 
mediated autoimmune destruction.  
Substitutive therapy of either AAD or POI is not influenced by presence or absence of 
autoantibodies, but identification of autoimmune forms of these disease is nevertheless 
important. Approximately two thirds of AAD patients have at least another associated 
autoimmune disease, either clinical or pre-clinical. Accordingly, screening for other 
autoimmune disorders is mandatory in autoimmune AAD, but not strictly necessary in 
other forms of PAI. More importantly, autoimmune POI has a distinct pathophysiology 
which differs from that of other forms of ovarian insufficiency. Detection of steroid-cell 
autoantibodies enables the identification of subjects with an initially preserved follicle pool.  
No animal models of spontaneous steroid-cell autoimmunity are currently available, and 
there is strong need for the generation of such models that may enable the improvement of 
our understanding of the molecular mechanisms of these diseases. 
During the next few years large multicentric studies are expected to be performed to 
identify subjects at high-risk for developing AAD and clinical trials are being planned with 
the aim of immunomodulate the adrenal autoimmune response and delay progression 
towards clinical AAD. The availability of novel immunological technologies will prove 
instrumental in the molecular characterization of the steroid cell autoantigens and peptides 
recognised by human autoreactive T cells responsible for the adrenocortical cell destruction. 
In addition, epidemiological studies are needed to provide novel insights on the role of 
putative environmental factors.  
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